Showing 8171-8180 of 9758 results for "".
- Tonight: DEF Webinar Series Kicks Off to Explore COVID-19 Impact on PAs, NPshttps://practicaldermatology.com/news/tonight-def-webinar-series-kicks-off-to-explore-covid-19-impact-on-pas-nps/2460331/Dermatology Education Foundation (DEF) tonight launches a new weekly video series that will focus on the impact of the COVID-19 crisis on dermatology NPs and PAs. Noting that this pandemic presents unprecedented personal and professional hardships and challenges to all practices, DEF ur
- Castle Creek Biosciences Scores $75M Investmenthttps://practicaldermatology.com/news/castle-creek-biosciences-scores-75m-investment-1/2460319/Castle Creek Biosciences, Inc. received $75 million to support the advancement of multiple gene therapy candidates for rare diseases. The company plans to use the funding to advance and expand its gene therapy pipeline, led by the Phase 3 clinical development of FCX-007
- CMS Updates Quality Reporting Requirements in Light of COVID-19https://practicaldermatology.com/news/cms-updates-quality-reporting-requirements/2460315/CMS is granting exceptions from reporting requirements and extensions for clinicians and providers participating in Medicare quality reporting programs with respect to upcoming measure reporting and data submission for those programs. For those programs with data submission deadl
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”
- Special Report: An Overview of Coronavirus by Dr. Jonathan Kaplanhttps://practicaldermatology.com/news/special-report-an-overview-of-coronavirus-by-dr-jonathan-kaplan/2460306/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less coll
- Neauvia’s Introduces Zaffiro, A Two-Part Solution to Skin Rejuvenationhttps://practicaldermatology.com/news/neuvias-introduces-zaffiro-a-two-part-solution-to-skin-rejuvenation/2460305/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuve
- Study: DermTech’s Non-Invasive Gene Expression Testing Improves Early Melanoma Detectionhttps://practicaldermatology.com/news/study-dermtechs-non-invasive-gene-expression-testing-improves-early-melanoma-detection/2460297/A large registry study confirms that DermTech Pigmented Lesion Assay can reduce unnecessary biopsies by up to 90 percent, lower healthcare costs, and rule out melanoma. “The DermTech PLA helps clinicians employ precision dermatology and harness genomics technology to detect malign
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- Dermatologists React to Threat of Coronavirus Pandemichttps://practicaldermatology.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic/2460291/Reports about COVID-19 are causing many dermatologists to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a “public health emerge
- Foamix’s Rosacea Candidate Shows Promise in Phase 3 Studieshttps://practicaldermatology.com/news/foamixs-rosacea-candidate-shows-promise-in-phase-3-studies-1/2460286/Foamix Pharmaceuticals Ltd.’s FMX103 1.5% Topical Minocycline Foam for rosacea performed well in an integrated efficacy analysis of two pivotal Phase 3 clinical trials presented at the 17th Annual South Beach Symposium in Dermatology in Miami,